Aeon Bioscience

Aeon Biopharma is a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA), for a range of therapeutic conditions. The company's lead candidate, ABP-450, is the same 900 kDa botulinum toxin type A complex used in the aesthetic product Jeuveau, for which Aeon holds exclusive therapeutic rights. Aeon is currently advancing clinical programs for the prevention of chronic migraine and the treatment of cervical dystonia, following a Phase 2 study in episodic migraine. By leveraging a toxin with a well-characterized safety and efficacy profile, Aeon aims to capture a significant share of the multi-billion dollar therapeutic neurotoxin market. The company is also exploring additional indications such as gastroparesis and post-traumatic stress disorder. Aeon Biopharma is headquartered in Newport Beach, California, and maintains a strategic manufacturing partnership with Daewoong Pharmaceutical.